CellRapeutics™ CAR-T Engineering Service Targeting TRBCs for T-cell Malignancies Immunotherapy

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Potential of TRBCs for T-cell Malignancies Immunotherapy

The αβ T-cell receptor (TCR) serves as a pan-T cell antigen which is highly expressed in T-cell malignancies. However, targeting the αβ TCR to treat T-cell malignancies would result in T-cell aplasia, which can cause severe immunosuppression. Meanwhile, it is impractical to generate customized drugs for each patient due to the diversity of T-cell clones in patients. Since T cells exclusively express either TRBC1 or TRBC2 in T-cell malignancy patients, the development of specific CAR-T cells targeting T-cell receptor β-chain constant region (TRBCs) may be more feasible for effective treatment of T-cell lymphoma.

Fig.1 T cells exclusively express either TRBC1 or TRBC2 in T-cell malignancies patients.¹

Our CellRapeutics™ TRBCs-targeted CAR-T engineering services

Leverage by our years of experience in the CAR-T field, Creative Biolabs provides novel TRBCs-targeted CAR-T engineering services to assist global customers' T cell malignancy therapy research. As T cell malignancies are highly heterogeneous in terms of oncogenic-driver pathways, we are committed to developing appropriate TRBCs-targeted CAR-T engineering services according to the variable needs of customers. At the same time, we offer a comprehensive range of services, including from CAR-T design & construction, and delivery system construction, to in vitro and in vivo validation to speed the process of customers' research.

Features of our TRBCs-targeted CAR-T Engineering Services

Compared to other common CAR-T approaches for T cell malignancies, this strategy has the following advantages:

Eradicating T-cell malignancies while retaining enough T cells to maintain normal cellular immunity.
Maintaining relative security.
It is suitable for subsets of T-cell malignancies that are independent of a complex oncogenic pathway.

Benefit for you

One-stop CAR-T development to assure our top-ranking service

Highly experienced scientists to assist CellRapeutics™ TRBCs-targeted CAR-T engineering services

Benefit for you

Reliable and reputable experiment systems to guarantee high-quality services

Comprehensive customized services to meet the variable needs of global customers

Data Speaking

Representative data 1: Anti-TRBC1 CAR-T for immunotherapy of T cell malignancies

Fig.2 In vivo efficacy and specificity validation of anti-TRBC1 CAR-T cells in T cell malignancy mouse model.1

Frequently Asked Questions

Q1: What are the challenges for TRBCs-targeted CAR-T engineering?

A1: In the TRBCs-targeted CAR-T engineering development process, how to ensure high effectiveness while avoiding possible security problems will always be a key consideration. Based on the years of CAR-T research experience, we adopt combination designs to compare and optimize, and at the same time conduct several safety monitoring to investigate the security issues of this strategy from multiple aspects of efficacy and safety evaluations.

Q2: Is it possible to develop a TCRV-targeted CAR-T engineering service?

A2: During T cell development, variable-diversity-joining (VDJ)-domain recombination leads to a diversity of T cell receptors, which results in unique TCR Vβ and Vα features in specific T cell clones. Due to the diversity of TCRV subtypes, developing TCRV-targeted CAR-T may be more diverse and flexible. If our customers need some related service, we are committed to developing custom services.

Work with Creative Biolabs

Work with Creative Biolabs. (Creative Biolabs Original)

For more details about our CellRapeutics™ TRBCs-targeted CAR-T engineering services, please feel free to contact us or send us a query.

Reference

Maciocia, P.M.; et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017, 23(12):1416-1423.